SCHEMBL5607912

SCHEMBL5607912

Cc1ccc(Oc2ccccc2-c2nnn[nH]2)c(O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.38
MEN1 O00255 7/20 0.38
ALOX15 P16050 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
HPGD P15428 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
TP53 P04637 3/20 0.38
LMNA P02545 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 6/20 0.36
USP2 O75604 3/20 0.36
ALDH1A1 P00352 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
GAA P10253 1/20 0.35
ALOX12 P18054 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5614136 0.86 CA3 (0.34) KMT2AMEN1ALOX15SMN1; SMN2NPC1
SCHEMBL5613919 0.85 IDO1 (0.36) KMT2AMEN1ALOX15SMN1; SMN2TP53
SCHEMBL5614004 0.85 TTR (0.47) KMT2AMEN1SMN1; SMN2HPGDNPC1
SCHEMBL5613924 0.80 KMT2A (0.43) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL9591725 0.80 GAA (0.43) KMT2AMEN1SMN1; SMN2HPGDNPC1
SCHEMBL5607371 0.78 KDM4E (0.52) KMT2AMEN1L3MBTL1ALDH1A1GAA
SCHEMBL5607415 0.78 AR (0.40) KMT2AMEN1NPC1RAB9ALMNA
SCHEMBL5628973 0.77 ALOX15 (0.40) KMT2AMEN1ALOX15SMN1; SMN2HPGD
SCHEMBL5613904 0.75 TTR (0.50) HPGDLMNAMAPTIDO1
SCHEMBL5905825 0.74 FTO (0.39) KMT2AMEN1ALOX15SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 KMT2A 3809/4885MEN1 4806/4885ALOX15 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.